Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
A vaccine based on autoclaved Mycobacterium w was administered, in addition to standard multidrug therapy (MDT), to 157 bacteriologically positive, lepromin-negative, multibacillary leprosy patients supported by a well-matched control group of 147 patients with similar type of disease who received a placebo injection in addition to MDT. The MDT was given for a minimum period of 2 years and continued until skin-smear negativity, while the vaccine/placebo was given at 3-month intervals up to a maximum of 8 doses in the initial 2 years. The overall incidence of type 1 and type 2 reactions and neuritis during treatment and follow up was nearly equal in the patients in the vaccine and placebo groups; the differences were not statistically significant. The occurrence of disabilities, such as anesthesia, trophic ulcers, claw hand and grade 3 deformities, were not different statistically in the vaccine and placebo groups, an observation valid both for deformities present at induction and for those which developed during the course of therapy and surveillance. A statistically significant difference was observed in the recovery of newly developed trophic ulcers; recovery was quicker in the vaccine group. The recovery rate for motor deformities was marginally higher in the vaccine group, although not significant (p = 0.068) statistically. There was a statistically significant reduction in the incidence of grade 3 deformities following MDT with and without immunotherapy. To conclude, the addition of vaccine to MDT did not precipitate neuritis or deformities over and above that encountered with MDT alone, although it did accelerate bacteriological clearance, histopathological upgrading, conversion to lepromin positivity, and clinical improvement.
Sharma
P
P
National Institute of Immunology, New Delhi, India. rajni@nii.res.in
Kar
H K
HK
Misra
R S
RS
Mukherjee
A
A
Kaur
H
H
Mukherjee
R
R
Rani
R
R
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D002991:Clofazimine / Q000627:therapeutic use; D006233:Persons with Disabilities / Q000706:statistics & numerical data*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006227:Hand Deformities, Acquired / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015994:Incidence; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D009166:Mycobacterium leprae / Q000276:immunology* / Q000472:pathogenicity; D009443:Neuritis / Q000453:epidemiology / Q000517:prevention & control; D011239:Prednisolone / Q000627:therapeutic use; D014456:Ulcer / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D014774:Virulence
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001428:Bacterial Vaccines; D007917:Leprostatic Agents; D011239:Prednisolone; D002991:Clofazimine